SURVYR

BBNX

Beta Bionics, Inc.
$21.39
+$0.88 (4.29%)Oct 27 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-63%-38%-13%+13%+38%Oct 2025Oct 2026Apr 202652w high $32.7152w low $8.80
BBNXSPY
Wall St. Highest PT $30.40 (+42.1%) Wall St. Avg PT $24.24 (+13.3%)
$9$15$21$28$34POC $16Hi $30Avg $24
Underwater Drawdown %Max DD -72.3%Current -33.1%
0.0%-72.3%
Relative Strength vs SPY-23.5% vs SPYUnderperforming
+82%0%-82%
1W
+$3.65 (20.57%)
1M
−$0.12 (0.56%)
3M
+$5.59 (35.38%)
6M
+$11.31 (112.20%)
YTD
−$9.08 (29.80%)
1Y
−$2.36 (9.94%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Buy
14 analysts · mean score 1.67
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$21.39
Average target$24.24
+$2.85 (+13.3%) upsideaverage target vs current price
CurrentAverageMedian
Low$16.00
Median$24.24
High$30.40
12-month Wall Street target range
Recent analyst rating changes · 30
Initiated
2026-10-12 · Jefferies started covering BBNX at Buy
Reiterated
2026-09-24 · Truist Securities reiterated Buy on BBNX
Initiated
2026-09-23 · Wells Fargo started covering BBNX at Overweight
Reiterated
2026-09-15 · B of A Securities reiterated Neutral on BBNX
Reiterated
2026-09-15 · Truist Securities reiterated Buy on BBNX
Reiterated
2026-09-15 · Baird reiterated Neutral on BBNX
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$1.0B
P/E (next 12 months, estimated)-8.9
52-week range$8.80 – $32.71
Revenue growth (latest quarter vs a year ago)+37.8%
Dividend yieldNo dividend
Analyst consensusBuy (14)
Average analyst price target$24.24 (+13%)

What they do

Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older.

Healthcare · Medical Devices
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for BBNX yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

BBNX earningsNext report in -1 days
Next report · quarter Sep 2026
Tue Oct 27, 2026After the close
EPS consensus-$0.51 range -$0.55–-$0.46
Revenue consensus$34.6M 10 analysts
Last 4 quarters · EPS vs estimate
Jul 29, 2026-$0.36est -$0.56+35.1%Above estimates
Apr 21, 2026-$0.36est -$0.45+21.1%Above estimates
Feb 17, 2026-$0.19est -$0.38+49.4%Above estimates
Oct 28, 2025-$0.33est -$0.41+19.8%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-23 23:44:16 ET
25-0325-0525-0725-1026-0226-0426-07-2.720.00
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$32.0M+37.8%
2026-03-31$27.6M–
2025-12-31$32.1M–
2025-09-30$27.3M–
2025-06-30$23.2M–

News & catalysts

More news
Beta Bionics (BBNX) Q3 2026 Earnings Call Transcript
Nasdaq · 5h ago
BBNX Deadline: BBNX Investors Have Opportunity to Lead Beta Bionics, Inc. Securities Fraud Lawsuit
PR Newswire · Oct 24
Beta Bionics, Inc. Notice of November 3, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
PR Newswire · Oct 23
BBNX INVESTOR DEADLINE: Beta Bionics Investors with Substantial Losses Have Opportunity to Lead Securities Class Action
PR Newswire · Oct 23
Beta Bionics (NASDAQ: BBNX) Faces Securities Fraud Class Action Amid iLet FDA Compliance - Hagens Berman
PR Newswire · Oct 21
Rating changes
Initiated
2026-10-12 · Jefferies started covering BBNX at Buy
Reiterated
2026-09-24 · Truist Securities reiterated Buy on BBNX
Initiated
2026-09-23 · Wells Fargo started covering BBNX at Overweight
Reiterated
2026-09-15 · B of A Securities reiterated Neutral on BBNX
Reiterated
2026-09-15 · Truist Securities reiterated Buy on BBNX
Reiterated
2026-09-15 · Baird reiterated Neutral on BBNX

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Hopman Mark
Chief Commercial Officer · 2026-10-14
Sell
$13.4K
Hopman Mark
Chief Commercial Officer · 2026-10-01
Sell
$7.0K
Jones Christy
Director · 2026-09-22
Sell
$147.9K
Mensinger Mike
Chief Product Officer · 2026-09-16
Sell
$58.3K
Hopman Mark
Chief Commercial Officer · 2026-09-16
Sell
$619.6K
Hopman Mark
Chief Commercial Officer · 2026-09-14
Sell
$12.0K
Hopman Mark
Chief Commercial Officer · 2026-09-09
Sell
$680.7K
Saint Sean
Director, President & CEO · 2026-09-03
Sell
$113.3K
Saint Sean
Director, President & CEO · 2026-09-02
Sell
$322.4K
Feider Stephen
Chief Financial Officer · 2026-09-02
Sell
$127.6K
Mensinger Mike
Chief Product Officer · 2026-09-02
Sell
$83.6K
Russell Steven Jon
Chief Medical Officer · 2026-09-02
Sell
$80.7K

Stats refreshed 2026-10-23 23:44:16 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026